Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

243.77 -4.47 (-1.80%)
Delayed Quote Updated: 1:10 PM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Cannabis Stocks Are Splitting Into Profitable Leaders and Sentiment-Driven Laggards ↗
Via Chartmill
Topics Cannabis
News headline image
Jazz Pharmaceuticals (JAZZ) shares skyrocket, what you need to know
What happened? Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 8.4% in the afternoon session after the company reported record revenue ... 
Via StockStory
News headline image
JAZZ Q3 deep dive: oncology momentum and new launches offset margin pressure
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q3 2026, with sales up 10.4% year on year to $1.24 billion. T... 
Via StockStory
News headline image
Jazz (JAZZ) Q3 2026 Earnings Call Transcript ↗
Oncology portfolio surges 35% as Ziihera launches and Xywav sustains momentum. 
Via The Motley Fool
Topics Earnings
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 Results In Line as Raised Guidance Sparks After-Hours Surge ↗
Via Chartmill
Cannabis Stocks’ Rally Is Narrow as Profitable Healthcare and Consumer Names Do the Heavy Lifting ↗
Via Chartmill
Topics Cannabis
Jazz Pharmaceuticals (NASDAQ:JAZZ): An Undervalued Biopharma Value Stock ↗
Via Chartmill
News headline image
Jazz Pharmaceuticals Q3 Earnings Call Highlights ↗
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported record third-quarter revenue of $1.24 billion, up 10% from a year earlier, and raised its full-year 2026 revenue outlook as growth in its sleep and oncology... 
Via MarketBeat
Topics Cannabis Earnings
News headline image
Jazz Pharmaceuticals (NASDAQ:JAZZ) surprises with Q3 2026 sales, full-year sales guidance is optimistic
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.4% year on year to $1.24 bill... 
Via StockStory
News headline image
What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earnings
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Monday after market hours. Here’s what to expect. Jazz Pharmaceuticals be... 
Via StockStory
News headline image
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine ↗
Jazz Pharmaceuticals' strategy is starting to pay dividends. 
Via The Motley Fool
Cannabis Stocks Aren’t a Recovery Trade: Narrow Leadership Splits Quality and Momentum ↗
Via Chartmill
Topics Cannabis
Cannabis Stocks: A Profitability Turnaround Is Brewing Beneath Weak Price Action ↗
Via Chartmill
Topics Cannabis
News headline image
3 Healthcare Stocks That Concern Us
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks That Fall Short
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NAS... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B ↗
Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the... 
Via MarketBeat
Topics Cannabis
Jazz Pharmaceuticals (NASDAQ:JAZZ): A Decent Value Stock Trading Below Its Worth ↗
Via Chartmill
Cannabis Rally Turns Selective as Investors Reward Pharma-Tinged Names ↗
Via Chartmill
Topics Cannabis
Jazz Pharmaceuticals (NASDAQ:JAZZ): A Decent Value Opportunity ↗
Via Chartmill
News headline image
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands ↗
Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the... 
Via MarketBeat
Topics Cannabis
News headline image
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? ↗
Actio could make Jazz's growing epilepsy franchise even stronger. 
Via The Motley Fool
News headline image
3 Cash-Producing Stocks We’re Skeptical Of
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
Topics Retirement
News headline image
2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead
Jazz Pharmaceuticals’s 29.7% return over the past six months has outpaced the S&P 500 by 17%, and its stock price has climbed to $240.49 per share. This was ... 
Via StockStory
Topics Stocks
News headline image
1 Value Stock with Exciting Potential and 2 We Brush Off
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
Via StockStory
Topics Energy Retirement
News headline image
Stocks making big moves yesterday: Jazz Pharmaceuticals, SAIC, Herbalife, AGCO, and Deere
Check out the companies making headlines yesterday: Jazz Pharmaceuticals (NASDAQ:JAZZ): Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) rose by 2.5% on ... 
Via StockStory
News headline image
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
What Happened? Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 2.5% in the afternoon session after the company announced positive Phase... 
Via StockStory
Topics Artificial Intelligence
News headline image
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA ↗
Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic... 
Via MarketBeat
Topics Cannabis
News headline image
3 Profitable Stocks with Questionable Fundamentals
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
Topics Economy
News headline image
Jazz Pharmaceuticals (JAZZ) Q2 2026 Earnings Call Transcript ↗
Revenue hit $1.2 billion with oncology sales surging and Xywav demand accelerating. 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.